ArticleBritish journal of haematology2023
Reply to: Can circulating CD34+ cells count be used for the prognosis of myelofibrosis? Probably yes, at least in patients treated with ruxolitinib.
Alessandra Iurlo et al.PubMed ↗Publisher ↗
No numbers read from the abstract.